Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 24_CPCR_38 | Other Identifier | ChristieNHS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| CellCentric Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.
People can receive many lines of treatment for multiple myeloma. The investigators would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to participants when considering treatment options, how participants experiences have differed with different treatments and if participants have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. Participants will be asked to take part in an interview which should take approximately 30 minutes to an hour. During the interview, participants will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient Interviews | Participants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patient Interview | Other | Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Patient Experience and Preference | The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions. | 30-60 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment and Preference Differences | The interview will explore how experiences have differed across different lines of treatment and determine if people with multiple myeloma have any preferences for particular treatments. | 30-60 minutes |
Not provided
Inclusion Criteria:
Participants with confirmed MM (per standard disease specific diagnostic criteria)
Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories:
Aged 18 years of age or over
Able to provide informed consent
Able to communicate in English
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with multiple myeloma who have received at least five lines of treatment.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sally Taylor, PhD | The Christie NHS Foundation Trust | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Christie NHS Foundation Trust | Manchester | Greater Manchester | M20 4BX | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42080199 | Derived | Perry MB, Lochhead Devaraj R, Law K, Ashby F, Taylor S. iPREFER: Patients' Experiences and Preference of Treatment for Multiple Myeloma Following Multiple Lines of Treatment - A Qualitative Study. Patient Prefer Adherence. 2026 Apr 28;20:576524. doi: 10.2147/PPA.S576524. eCollection 2026. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |